Iright
BRAND / VENDOR: Biolegend

Biolegend, 369302, Purified anti-human CD223 (LAG-3) Antibody, 100μg

CATALOG NUMBER: 369302
السعر العادي$0.99
/
  • In stock, ready to ship

  • الطلب مؤجل، سيتم الشحن قريباً

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Product Description

CD223, also known as LAG-3, is a 70 kD type I transmembrane glycoprotein that is involved in T-cell signaling. Similar to CD4, CD223 binds MHC class II, but with a higher affinity. CD223 negatively regulates T-cell activation. It is expressed by activated T-cells and natural killer cells (NKs), as well as regulatory T-cells. It is transiently expressed on the surface of activated T-cells in acute conditions but high expression is maintained under tolerizing conditions. CD223 deficiency results in reduced tumor growth. CD223 and PD-1 can act in synergy and reverse exhausted phenotypes, improve tumor rejection, and control viral load.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human LAG-3 transfected cells.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: The staining of clone 11C3C65 cannot be blocked by clone 7H2C65, which is another anti-human CD223 (LAG-3) antibody.
Product Citations: Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed Gide TN, et al. 2019. Cancer Cell. 35:238. PubMed Tian Y, et al. 2019. Cell Rep. 29:4482. PubMed Liu F, et al. 2020. J Immunother Cancer. 8:. PubMed O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed Cobb DA, et al. 2022. J Immunother Cancer. 10:. PubMed Schulte–Schrepping J, et al. 2020. Cell. 182(6):1419-1440. PubMed Macmillan ML, et al. 2021. Blood Adv. 5:1425. PubMed Georg P, et al. 2022. Cell. 185:493. PubMed
RRID: AB_2616876 (BioLegend Cat. No. 369302)
Structure: 70 kD transmembrane glycoprotein, Ig superfamily, highly homologous to CD4.
Distribution: Activated T-cells and natural killer cells (NKs) and regulatory T cells.
Function: Negatively regulates T-cell activation.
Ligand/Receptor: Binds MHC class II molecules.
Cell Type: Dendritic cells, NK cells, T cells, Tregs
Biology Area: Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Castelli C, et al. 2014. Oncoimmunology. 3(11):e967146. 2. Poirier N, et al. 2011. Clin. Exp. Immunol. 164:265. 3. Juno JA, et al. 2015. Retrovirology. 12:17. 4. Casati C, et al. 2006. Cancer Res. 66:4450.
Gene ID: 3902
UniProt: View information about CD223 on UniProt.org
Clone: 11C3C65
Regulatory Status: RUO
Other Names: CD223, LAG-3, LAG3, lymphocyte-activation gene-3
Isotype: Mouse IgG1, κ


Order Guidelines

1. Price & Stock Available on Request. 📧Click to send email to: service@iright.com

2. Please DO NOT make payment before confirmation.

3. Minimum order value of $1,000 USD required.

Collaboration

Tony Tang

📧Email: Tony.Tang@iright.com

📱Mobile/WhatsApp/Wechat: +86-17717886924